Abstract No : Abstract 1257O
Indication : Non-small cell lung cancer
Intervention : Sotorasib (AMG 510)
Company : Amgen
Technology : KRAS protein inhibitors
Results:
Sotorasib demonstrated confirmed objective response rate (ORR) and disease control rates (DCR) of 35.3% and 91.2%, respectively, in 34 heavily pretreated patients (median of two prior lines of therapy) with NSCLC, who were treated with the 960 mg daily dose (data cutoff of June 1, 2020).
Anticancer activity was seen across all dose levels in patients with NSCLC, with a confirmed ORR of 32.2% and DCR of 88.1%, and median duration of response of 10.9 months, with 10 of 19 responders still in response as of the data cutoff. Tumor shrinkage was observed in 71.2% of patients at the first week-6 assessment. Median progression-free survival (mPFS) in patients treated with sotorasib was 6.3 months.
Conclusion:
Sotorasib demonstrated encouraging clinical benefit in heavily pretreated NSCLC patients with KRAS mutation and also showed a favourable safety profile
